Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Investigators at Research Center zero in on cancer vaccines
September 17th, 2008
"Compelling evidences indicate a key role for regulatory T cells (T-reg) on the host response to cancer. The Wilms' tumor antigen (WT1) is overexpressed in several human leukemias and thus considered as promising target for development of leukemia vaccine," investigators in Riyadh, Saudi Arabia report. "However, recent studies indicated that the generation of effective WT1-specific cytotoxic T cells can be largely affected by the presence of T-regs. We have generated T-cell lines and clones that specifically recognized a WT1-84 (RYFKLSHLQMHSRKH) peptide in an HLA-DRBI*0402-restricted manner. Importantly, they recognized HLA-DRBI*04-matched fresh leukemic cells...
Source: Vaccine Weekly (2008-09-17)
|
